<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="110964">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01922765</url>
  </required_header>
  <id_info>
    <org_study_id>concomitant</org_study_id>
    <nct_id>NCT01922765</nct_id>
  </id_info>
  <brief_title>Concomitant Therapy of H. Pylori</brief_title>
  <official_title>Evaluation of the Efficacy of Concomitant Therapy for Eradication of Helicobacter Pylori</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The Catholic University of Korea</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>St.Vincent Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>The Catholic University of Korea</source>
  <oversight_info>
    <authority>Korea: Ministry of Education, Science, and Technology</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      If we compare eradication rate of Helicobacter pylori divided to 4 groups: amoxicillin,
      rabeprazole, clarithromycin(AOC), amoxicillin, rabeprazole, metronidazole(AOM), treated with
      amoxicillin, rabeprazole for 5 day, followed by clarithromycin, metronidazole, rabeprazole
      for 5 days(sequential), amoxicillin, clarithromycin, metronidazole,
      rabeprazole(concomitant), then the eradication rate of concomitant group will be the
      highest.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      -  Subject: The patient of gastritis, gastric ulcer, and duodenal ulcer infected with
           Helicobacter pylori

        -  170 subjects per group

        -  Eradication regimens are as follows: AOC group, treated with amoxicillin, rabeprazole,
           clarithromycin for 7 days; AOM group, treated with amoxicillin, rabeprazole,
           metronidazole for 7 days; sequential group, treated with amoxicillin, rabeprazole for 5
           day, followed by clarithromycin, metronidazole, rabeprazole for 5 days; concomitant
           group, treated with amoxicillin, clarithromycin, metronidazole, rabeprazole for 7 days
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>August 2013</start_date>
  <completion_date type="Anticipated">February 2014</completion_date>
  <primary_completion_date type="Anticipated">February 2014</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Evaluation of the efficacy of concomitant therapy for eradication of Helicobacter pylori</measure>
    <time_frame>6 months (Feb 2014)</time_frame>
    <safety_issue>No</safety_issue>
    <description>measure eradication rate of H.pylori with urea breath test(UBT) after 6 to 8 weeks of treatment</description>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">540</enrollment>
  <condition>Gastritis, Gastric Ulcer, and Duodenal Ulcer</condition>
  <arm_group>
    <arm_group_label>AOC group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>AOC group: treated with amoxicillin, rabeprazole, clarithromycin for 7 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>AOM group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>AOM group: treated with amoxicillin, rabeprazole, metronidazole for 7 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sequential group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Sequential group: treated with amoxicillin, rabeprazole for 5 day, followed by clarithromycin, metronidazole, rabeprazole for 5 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>concomitant group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>concomitant group: treated with amoxicillin, clarithromycin, metronidazole, rabeprazole for 7 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>amoxicillin, clarithromycin, metronidazole, rabeprazole</intervention_name>
    <arm_group_label>AOC group</arm_group_label>
    <arm_group_label>AOM group</arm_group_label>
    <arm_group_label>Sequential group</arm_group_label>
    <arm_group_label>concomitant group</arm_group_label>
    <other_name>AOC group: treated with amoxicillin, rabeprazole, clarithromycin for 7 days</other_name>
    <other_name>AOM group: treated with amoxicillin, rabeprazole, metronidazole for 7 days</other_name>
    <other_name>Sequential group: treated with amoxicillin, rabeprazole for 5 day, followed by clarithromycin, metronidazole, rabeprazole for 5 days</other_name>
    <other_name>concomitant group: treated with amoxicillin, clarithromycin, metronidazole, rabeprazole for 7 days</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  patients infected with Helicobacter pylori

        Exclusion Criteria:

          -  cancer

          -  pregnancy

          -  formerly treated with eradication
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Yeouido St. Mary's Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>150-713</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jin Il Kim, MD,PhD</last_name>
      <phone>82-10-6345-9977</phone>
      <email>jikim@catholic.ac.kr</email>
    </contact>
    <investigator>
      <last_name>Jin Il Kim, MD,PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>February 2014</verification_date>
  <lastchanged_date>February 9, 2014</lastchanged_date>
  <firstreceived_date>August 12, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>The Catholic University of Korea</investigator_affiliation>
    <investigator_full_name>Jin Il Kim</investigator_full_name>
    <investigator_title>MD, PhD</investigator_title>
  </responsible_party>
  <keyword>Helicobacter</keyword>
  <keyword>Eradication</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Duodenal Ulcer</mesh_term>
    <mesh_term>Gastritis</mesh_term>
    <mesh_term>Stomach Ulcer</mesh_term>
    <mesh_term>Ulcer</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Amoxicillin</mesh_term>
    <mesh_term>Clarithromycin</mesh_term>
    <mesh_term>Metronidazole</mesh_term>
    <mesh_term>Rabeprazole</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
